Fluoride therapy in metabolic bone disease.
Multiple forms of treatment are used for osteoporosis, Paget's disease of the bone, and osteogenesis imperfecta. Because of the effect of fluoride (F) on bone, these bone conditions may benefit from F therapy. In the present study, the metabolic effects of two dose levels of F (20 and 45 mg, given as sodium fluoride) were studied on calcium (Ca) and F metabolism in patients with osteoporosis, whereas the effect of the 45-mg dose was studied in patients with Paget's disease. In patients with osteoporosis, the retention of F increased with increasing F intake, indicating F deposition in bone. However, only the 45-mg dose decreased urinary Ca excretion. F did not decrease fecal Ca excretion, indicating that the intestinal absorption of Ca did not improve during F therapy. This was confirmed in 47Ca absorption studies. The duration of F therapy was 3 months, utilizing the 45-mg dose. Clinically, the patients experienced relief of bone pain, and the onset of this change coincided with the decrease in urinary Ca. The 3-month course of treatment was sufficient for alleviation of clinical symptoms for many months and even years. In patients with Paget's disease, F supplements decreased urinary Ca and also resulted in relief of bone pain. F therapy for osteogenesis imperfecta resulted in decreased fracture incidence.
D002118:Calcium / Q000378:metabolism* / Q000652:urine; D005459:Fluorides / Q000378:metabolism* / Q000652:urine; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D008297:Male; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000378:metabolism; D010013:Osteogenesis Imperfecta / Q000188:drug therapy / Q000378:metabolism; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism; D012969:Sodium Fluoride / Q000494:pharmacology / Q000627:therapeutic use*
D012969:Sodium Fluoride; D005459:Fluorides; D002118:Calcium